Moderna Stock News
$258.38
13.11%
Nasdaq, Nov 04, 04:28 pm EST.
Closed.
Why the stock moved Beta
Index
Industry
Moderna Stock News
Stanley Black & Decker's stock was the strongest performer among the S&P 500, while several tech players and associated power providers showed sharp declines.
In another busy earnings week, AMD, Estée Lauder, Qualcomm, Pfizer, and many more will report results. We'll see three readings on jobs this week, as well as data on the manufacturing and services sectors.
Stéphane Bancel defended his melanoma data and argued that rivals can't easily copy the technology.
Moderna CEO Stéphane Bancel says the biotech's competitive edge stems from its mRNA platform, likening it to software in Big Tech.
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker's experimental cancer treatment.
Even after its latest sharp fall, the drugmaker's stock price assumes wild successes.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
